Skeletal metastases in non-small cell lung cancer: A retrospective study

Lung Cancer

Volumn 57, Issue 2, 2007, Pages 229-232

  Tsuya, Asuka ^a   Kurata, Takayasu ^b   Tamura, Kenji ^c   Fukuoka, Masahiro ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HYOGO MEDICAL CENTER FOR ADULTS   (Japan)

^c KINDAI UNIVERSITY NARA HOSPITAL   (Japan)

Author keywords

Bisphosphonate; Median survival; Non small cell lung cancer; Retrospective study; Skeletal metastasis; Skeletal related event

Indexed keywords

ADULT; ADVANCED CANCER; ANALGESIA; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CANCER STAGING; CANCER SURVIVAL; CLINICAL ASSESSMENT; DISEASE COURSE; FEMALE; HUMAN; HYPERCALCEMIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; X RAY ANALYSIS;

ANALGESICS; BONE NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; DIPHOSPHONATES; FRACTURES, SPONTANEOUS; HUMANS; HYPERCALCEMIA; JAPAN; LUNG NEOPLASMS; NEOPLASM STAGING; PAIN; RADIOTHERAPY; RETROSPECTIVE STUDIES; SPINAL CORD COMPRESSION; SURVIVAL ANALYSIS;

EID: 34447278130     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2007.03.013     Document Type: Article

References (15)

1. Woodhouse E.C., Chuaqui R.F., and Liotta L.A. General mechanisms of metastases. Cancer 80 (1997) 1529-1537
2. Coleman R.E. Skeletal complications of malignancy. Cancer 80 (1997) 1588-1594
3. Kosteva J., and Langer C.J. Incidence and distribution of skeletal metastases in NSCLC in the era of PET. Lung Cancer 46 Suppl 1 (2004) S45 [Abstract]
4. Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain 69 (1997) 1-18
5. Delea T., Langer C., McKiernan J., Liss M., Edelsberg J., Brandman J., et al. The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer. Oncology 67 (2004) 390-396
6. Rosen L.S., Gordon D., Tchekmedyian S., Yanagihara R., Hirsh V., Krzakowski M., et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double blind, randomized trial-the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 21 (2003) 3150-3157
7. Rosen L.S., Gordon D., Tchekmedyian N.S., Yanagihara R., Hirsh V., Krzakowski M., et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with non-small cell lung carcinoma and other solid tumors; a randomized phase III, double-blind, placebo-controlled trial. Cancer 100 (2004) 2613-2621
8. Body J.J., Lortholary A., Romieu G., Vigneron A.M., and Ford J. A dose-finding study of zoledronate in hypercalcemic cancer patients. J Bone Miner Res 14 (1999) 1557-1561
9. Major P., Lortholary A., Hon J., Abdi E., Mills G., Menssen H.D., et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy; a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 19 (2001) 558-567
10. Berenson J.R., Rosen L.S., Howell A., Porter L., Coleman R.E., Morley W., et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 91 (2001) 1191-1200
11. Rosen L.S., Gordon D., Kaminski M., Howell A., Belch A., Mackey J., et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma; a randomized, double blind, multicenter, comparative trial. Cancer 98 (2003) 1735-1744
12. Saad F., Gleason D.M., and Murray R. Zoledronic acid is well tolerated for up to 24 months and significantly reduces skeletal complications in patients with advanced prostate cancer metastatic to bone. J Urol 169 Suppl (2003) [Abstract 394]
13. Saad F., Gleason D.M., Murray R., Tchekmedyian S., Venner P., Lacombe L., et al. long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96 11 (2004) 879-882
14. Saad F., Gleason D.M., Murray R., Tchekmedyian S., Venner P., Lacombe L., et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94 (2002) 1458-1468
15. Green J.R. Bisphosphonates: preclinical review. Oncologist 9 (2004) 3-13